


Figure 2. Mortality Multivariate Cox Models of Medicaid Expansion for the 4 Top Cancers During Each Period



Full model and covariates not presented for brevity. Patients treated by states that expanded Medicaid earlier than January 2014 were excluded to avoid capturing the effects of expansion during the later period. HR indicates hazard ratio.

pansion states. These findings are consistent with age-adjusted state cancer mortality data reported by the US Centers for Disease Control and Prevention, which do not clearly demonstrate a difference that favors either expansion or nonexpansion states (Figure 1).⁴

Baseline cancer mortality between expansion and nonexpansion states being the same after adjusting for predictors of cancer outcomes known to differ from state to state suggests similar care is being offered in different states. Clinically meaningful baseline differences in cancer survival between expansion and nonexpansion states before the US Affordable Care Act, combined with unmeasured social, community-level, and state Medicaid program differences, could obscure any association of Medicaid expansion with cancer survival (unpublished data; Ermer 2021). Moreover, similar baseline trends are a key assumption of difference-in-difference analysis, which is one of the most common statistical approaches currently used to study expansion.

One of the limitations of this study is that despite capturing 70% of new cancer diagnoses, the National Cancer Database only captures data from 30% of US hospitals.⁵ Therefore, potential differences in mortality across states secondary to noncaptured hospitals are not represented. However, the study indicates that, overall, similar cancer care is being offered in states that did and did not expand Medicaid. Establishing this baseline is critical in accurately describing and characterizing the association that Medicaid expansion might have with cancer survival.

Michelle C. Salazar, MD
 Michael F. Kaminski
 Maureen E. Canavan, PhD, MPH
 Richard C. Maduka, MD
 Andrew X. Li, MD
 Theresa Ermer, MD
 Daniel J. Boffa, MD

Author Affiliations: Division of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut (Salazar, Kaminski, Canavan, Maduka, Li, Ermer, Boffa); National Clinician Scholars Program, Yale University School of Medicine, New Haven, Connecticut (Salazar); Cancer Outcomes Public Policy and Effectiveness Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut (Canavan); Faculty of Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany (Ermer); London School of Hygiene & Tropical Medicine, University of London, London, England (Ermer).

Accepted for Publication: May 7, 2021.

Published Online: July 22, 2021. doi:10.1001/jamaoncol.2021.2582

Corresponding Author: Daniel J. Boffa, MD, Division of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, PO Box 208062, New Haven, CT 06520-8062 (daniel.boffa@yale.edu).

Author Contributions Drs Salazar and Canavan had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Salazar, Canavan, Ermer, Boffa.

Acquisition, analysis, or interpretation of data: Salazar, Kaminski, Canavan, Maduka, Li.

Drafting of the manuscript: Salazar, Kaminski, Boffa.

Critical revision of the manuscript for important intellectual content:

Salazar, Canavan, Maduka, Li, Ermer, Boffa.

Statistical analysis: Salazar, Kaminski, Canavan.

Administrative, technical, or material support: Canavan, Ermer, Boffa.

Supervision: Boffa.

Conflict of Interest Disclosures: Dr Boffa reported nonfinancial support from Epic Sciences outside the submitted work. No other disclosures were reported.

Funding/Support: This project was made possible by the Yale National Clinician Scholars Program and by Clinical and Translational Science Awards grant TL1 TRO01864 from the National Center for Advancing Translational Science, a component of the National Institutes of Health (NIH).

Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: This article's contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.

1. Emanuel EJ, Gluck R. *The Trillion Dollar Revolution: How the Affordable Care Act Transformed Politics, Law, and Health Care in America*. PublicAffairs; 2020.
2. Parikh-Patel A, Morris CR, Kizer KW. Disparities in quality of cancer care: the role of health insurance and population demographics. *Medicine (Baltimore)*. 2017;96(50):e9125. doi:10.1097/MD.0000000000009125
3. Jemal A, Lin CC, Davidoff AJ, Han X. Changes in insurance coverage and stage at diagnosis among nonelderly patients with cancer after the Affordable Care Act. *J Clin Oncol*. 2017;35(35):3906-3915. doi:10.1200/JCO.2017.73.7817
4. US Centers for Disease Control and Prevention. Cancer mortality by states. Accessed March 22, 2021. https://www.cdc.gov/nchs/pressroom/sosmap/cancer_mortality/cancer.htm
5. Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY. Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. *J Clin Oncol*. 2009;27(25):4177-4181. doi:10.1200/JCO.2008.21.7018

Incidence of Axillary Adenopathy in Breast Imaging After COVID-19 Vaccination

Vaccine-induced adenopathy after COVID-19 vaccination in breast imaging has received significant media attention, with evolving literary correspondence on management. Patients' self-report of axillary swelling following COVID-19 vaccination was reported as high as 16%.¹ The National Comprehensive Cancer Network and Society of Breast Imaging recommended to consider scheduling screening breast imaging 4 to 6 weeks after the second COVID-19 vac-

Table. Characteristics of Patients With and Without Adenopathy After COVID-19 Vaccination

Characteristic	No. (%)		P value
	Patients with adenopathy (n = 23)	Patients without adenopathy (n = 727)	
Age, median (range), y	64 (35-83)	67 (31-94)	.29
Type of imaging			.01
Diagnostic mammogram	6 (13.6)	38 (86.4)	
Screening mammogram	17 (2.4)	689 (97.6)	
Symptomatic			.01
No	21 (2.8)	724 (97.2)	
Yes	2 (40.0)	3 (60)	
Vaccine brand			.70
Moderna	14 (3.1)	432 (96.9)	
Pfizer	7 (2.4)	283 (97.6)	
Other ^a	0	5 (100)	
Unknown	2	7	
Vaccine dose			.34
First	4 (1.8)	219 (98.2)	
Second	18 (3.4)	507 (96.6)	
Unknown	1	1	
Days from vaccine, median	10 (1.0-28.0)	18.0 (1.0-85.0)	<.001
Days from vaccine			.01
1-14	15 (5.3)	268 (94.7)	
15-28	8 (2.9)	264 (97.1)	
>28	0	195 (100)	
BIRADS results			<.001
Missing	0	1	
0	15 (21.4)	55 (78.6)	
1	0	365 (100)	
2	2 (0.7)	294 (99.3)	
3	5 (45.5)	6 (54.5)	
4	0	5 (100)	
5	1 (100)	0	
6	0	1 (100)	

Abbreviation: BIRADS, Breast Imaging Reporting and Data System.

^a Other vaccines include Johnson & Johnson and Novavax vaccines.

cination dose when possible.² However, the actual incidence, timing, and characteristics of mammographic axillary adenopathy following COVID-19 vaccination remain uncertain.

Methods | Retrospective analysis was carried out assessing patients who received at least 1 injection of COVID-19 vaccine fewer than 90 days prior to either screening or diagnostic mammography at the Jacoby Center for Breast Health, Mayo Clinic, Florida, between January 15 and March 22, 2021. Information regarding COVID-19 vaccination and symptomatic adenopathy was inquired by technicians performing mammography and documented in the electronic medical record. Axillary adenopathy was assessed by interpreting radiologists and all adenopathy cases were re-reviewed. Wilcoxon rank-sum test and Fisher exact test were used to compare continuous and categorical variables, respectively. Multivariable logistic regression model was used to evaluate the association between days from vaccine and adenopathy. Receiver operating curve (ROC) analysis was used to assess potential cutoff days after vaccine and adenopathy. The analysis was done using R version

3.6.2. This study and waiver of informed consent were approved by Mayo Clinic Institutional Review Board.

Results | Of 750 women total, 23 (3%) patients had axillary adenopathy on mammography and only 2 patients were symptomatic (Table). As summarized in the Table, presence of symptoms was associated with abnormal imaging (40% vs 60%, $P = .01$) but not age (median [range] 64 [35-83] vs 67 [31-94]; $P = .29$) and type of vaccine ($P = .70$). Most patients with adenopathy had their second vaccination prior to breast imaging (18 out of 23 patients). However, there was no significant difference between the incidence of adenopathy after the first or second vaccination ($P = .34$).

The median time after vaccine in patients with adenopathy was significantly shorter at 10 days compared with 18 days in patients without adenopathy (median [range] 10 [1-28] vs 18 [1-85] days; $P < .001$). Adenopathy rates decreased as days from vaccine increased with 15 of 283 (5.3%) for 1 to 14 days, 8 of 272 (2.9%) for 15 to 28 days, and 0 of 195 (0%) for more than 28 days ($P = .01$). Using ROC analysis to identify the potential cutoff value of days after vaccination, the area under the ROC

curve was 0.72 (95% CI, 0.63-0.81) with the potential cutoff of 22.5 days.

The spectrum of mammography findings ranged from a single enlarged lymph node, to multiple enlarged lymph nodes, to adenopathy with soft tissue stranding. Additional imaging with ultrasonography was requested for 21 patients. At the time of this article, 17 ultrasonography examinations had been performed. Ultrasonography findings ranged from mildly prominent nodes with a preserved fatty hilum to rounded nodes demonstrating apparent loss of a fatty hilum. Follow-up imaging recommendations included no follow-up (n = 2), repeated ultrasonography with or without mammogram in 3 months (n = 14), and biopsy (n = 1). Biopsy was recommended for a patient with an ipsilateral breast cancer. Biopsy findings for this patient were negative for malignancy, and the adenopathy was presumably vaccine induced.

Discussion | While the incidence of COVID-19 vaccine-induced adenopathy in our study appeared to be low at 3% compared with 16% of self-reported axillary swelling in previous COVID-19 vaccine trials, this incidence is still higher than axillary adenopathy in otherwise normal mammography, which was reported as 0.02% to 0.04%.³ Therefore, routine inquiring about recent history of COVID-19 vaccination is warranted. The incidence of adenopathy decreased over time with no adenopathy seen in patients who received the vaccine more than 28 days previously, which supports the recommendations from Society of Breast Imaging. In addition, patients with symptomatic adenopathy are more likely to have adenopathy (odds ratio, 28.97; 95% CI, 3.23-226.09; $P = .01$). However, the present study has limitations, particularly with its small sample size and being a single center study. As COVID-19 vaccination is rolling out around the world, this study offers timing considerations and possible findings for breast imaging following vaccination. Further studies are needed to guide future recommendations for following up with patients with adenopathy after vaccination and evaluating findings with other imaging modalities.

Kristin A. Robinson, MD
Santo Maimone, MD
Denise A. Gococo-Benore, MD
Zhuo Li, MS
Pooja P. Advani, MD
Saranya Chumsri, MD

Author Affiliations: Department of Radiology, Mayo Clinic, Jacksonville, Florida (Robinson, Maimone); Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida (Gococo-Benore); Department of Quantitative Health Science, Mayo Clinic, Jacksonville, Florida (Li); Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida (Advani, Chumsri).

Accepted for Publication: May 25, 2021.

Published Online: July 22, 2021. doi:10.1001/jamaoncol.2021.3127

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2021 Robinson KA et al. *JAMA Oncology*.

Corresponding Author: Saranya Chumsri, MD, Division of Hematology and Medical Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224 (chumsri.saranya@mayo.edu).

Author Contributions: Dr Chumsri had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Robinson, Maimone, Advani, Chumsri.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Robinson, Maimone, Advani, Chumsri.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Maimone, Li, Advani, Chumsri.

Obtained funding: Chumsri.

Administrative, technical, or material support: Chumsri.

Supervision: Maimone, Chumsri.

Conflict of Interest Disclosures: Dr Advani reported grants from Genentech during the conduct of the study. Dr Chumsri reported grants from Pfizer during the conduct of the study; grants from Merck & Co, the Department of Defense, and the Breast Cancer Research Foundation; and personal fees from Novartis, Immunomedics, Puma Biotechnology, BioTherapeutics, AstraZeneca, Eisai, Athenex, and Daiichi Sankyo outside the submitted work. No other disclosures were reported.

Funding/Support: Research reported in this publication was supported by Mayo Clinic.

Role of the Funder/Sponsor: The Mayo Clinic had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

1. US Centers for Disease Control. Local reactions, systemic reactions, adverse events, and serious adverse events: Moderna COVID-19 Vaccine. Accessed June 15, 2021. <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html>
2. National Comprehensive Cancer Network. Recommendations of the NCCN COVID-19 Vaccination Advisory Committee. Accessed June 15, 2021. https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v3-0.pdf?
3. Lehman CD, Lamb LR, D'Alessandro HA. Mitigating the impact of coronavirus disease (COVID-19) vaccinations on patients undergoing breast imaging examinations: a pragmatic approach. *AJR Am J Roentgenol*. Published online February 22, 2021. doi:10.2214/AJR.21.25688

COMMENT & RESPONSE

Omission of Radiotherapy in Older Adults With Early-Stage Breast Cancer

To the Editor In their recent Viewpoint in *JAMA Oncology*, Chowdhary et al¹ provide a thorough overview on radiotherapeutic considerations for older adults with early-stage breast cancer. The authors suggest that shorter radiotherapy options could alter our recommendations in the spirit of “patient-centric care.” I respectfully disagree, and I believe that the authors are taking a paternalistic view without considering all the inputs of the decision-making process. While such options will change the calculus for individual patient decision-making, I do not believe that these emerging data will change our approach.

The decision to treat this group of patients with adjuvant radiotherapy should always be based on shared decision-making considering the pathological characteristics of the disease, the clinical condition of the patient, and the patient’s goals of care. We put into context the risks and benefits of treatment, combined with the physical and emotional implications of a recurrence. The authors cite the recent update of the PRIME II (Postoperative Radiotherapy in Minimum-Risk Elderly II) randomized clinical trial,² which demonstrated a reduction in ipsilateral breast tumor recurrence from 9.8% to 0.9% and in breast cancer-free survival from 12.7% to 6.6% without any difference in overall survival. While recurrence